ATE369375T1 - Synthese von locked nucleic acid-derivaten - Google Patents

Synthese von locked nucleic acid-derivaten

Info

Publication number
ATE369375T1
ATE369375T1 AT03718663T AT03718663T ATE369375T1 AT E369375 T1 ATE369375 T1 AT E369375T1 AT 03718663 T AT03718663 T AT 03718663T AT 03718663 T AT03718663 T AT 03718663T AT E369375 T1 ATE369375 T1 AT E369375T1
Authority
AT
Austria
Prior art keywords
lna
synthesis
nucleic acid
acid derivatives
locked nucleic
Prior art date
Application number
AT03718663T
Other languages
English (en)
Inventor
Mads Sorensen
Jesper Wengel
Troels Koch
Signe Christensen
Christoph Rosenbohm
Daniel Sejer Pedersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of ATE369375T1 publication Critical patent/ATE369375T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03718663T 2002-05-08 2003-05-08 Synthese von locked nucleic acid-derivaten ATE369375T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200712 2002-05-08
DKPA200201214 2002-08-16

Publications (1)

Publication Number Publication Date
ATE369375T1 true ATE369375T1 (de) 2007-08-15

Family

ID=29421786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718663T ATE369375T1 (de) 2002-05-08 2003-05-08 Synthese von locked nucleic acid-derivaten

Country Status (9)

Country Link
EP (1) EP1501848B1 (de)
JP (1) JP4476802B2 (de)
AT (1) ATE369375T1 (de)
AU (1) AU2003222743B2 (de)
CA (1) CA2484526C (de)
DE (1) DE60315444T2 (de)
DK (1) DK1501848T3 (de)
ES (1) ES2290448T3 (de)
WO (1) WO2003095467A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
ES2649817T3 (es) 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
EP2284269B1 (de) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense-Entwurf
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
ES2344566T3 (es) 2003-12-23 2010-08-31 Santaris Pharma A/S Compuestos oligomericos para la modulacion de bcl-2.
EP1824975B9 (de) 2004-11-09 2011-04-20 Santaris Pharma A/S Lna-oligonukleotide und krebsbehandlung
BRPI0515726A8 (pt) 2004-11-09 2017-09-12 Santaris Pharma As Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
EA201100811A1 (ru) 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20100062994A1 (en) * 2006-07-14 2010-03-11 Santaris Pharma A/S Adenosine Receptor Antagonists
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
US8470791B2 (en) 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
ES2798758T3 (es) 2007-06-06 2020-12-14 Sarepta Therapeutics Inc Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
EP2183360B1 (de) 2007-08-30 2017-01-11 Hadasit Medical Research Services&Development Company Ltd. Nukleinsäuresequenzen mit nf-(kappa)b-bindungsstelle innerhalb eines o(6)-methylguanin-dna-methyltransferase (mgmt)-promoter-bereichs und ihre verwendung zur behandlung von krebs und immunbedingten erkrankungen
JP5723154B2 (ja) 2007-09-19 2015-05-27 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
EP2268811A1 (de) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
US8492357B2 (en) 2008-08-01 2013-07-23 Santaris Pharma A/S Micro-RNA mediated modulation of colony stimulating factors
US9034837B2 (en) 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
EP3214174B1 (de) 2010-03-04 2019-10-16 InteRNA Technologies B.V. Mirna-molekül, das über seine quelle definiert ist, und seine diagnostischen und therapeutischen verwendungen bei mit emt assoziierten krankheiten
EP2591106A1 (de) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna und ihre diagnostischen und therapeutischen verwendungen für mit melanomen assoziierte erkrankungen oder leiden oder für mit dem aktivierten braf-pfad assoziierte erkrankungen oder leiden
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
CN103842387B (zh) * 2011-07-21 2017-04-26 罗地亚运作公司 瓜耳胶羟丙基三甲基氯化铵及其在发用处理组合物中的用途
EP3369818B1 (de) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna zur behandlung von kopf-hals-karzinom
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
EP2943570B1 (de) 2013-01-14 2018-01-03 Pierfrancesco Tassone Inhibitoren von mirnas 221 und 222 zur antitumorwirkung bei multiplem myelom
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
MX367083B (es) 2013-06-27 2019-08-05 Roche Innovation Ct Copenhagen As Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
EP3256586B1 (de) 2015-02-15 2021-04-07 Arcturus Therapeutics, Inc. Acyl-amino-lna- und/oder hydrocarbyl-amino-lna-oligonukleotide
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
CN116059236A (zh) 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017188898A1 (en) 2016-04-29 2017-11-02 Nanyang Technological University G-quadruplex-containing antisense oligonucleotides
US20220354888A1 (en) 2016-08-03 2022-11-10 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
KR20260009385A (ko) 2017-08-25 2026-01-19 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
AU2018358016A1 (en) 2017-11-03 2020-05-07 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
WO2019155094A1 (en) 2018-02-12 2019-08-15 Interna Technologies B.V. Anticancer microrna and lipid formulations thereof
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
IL304956A (en) 2021-02-12 2023-10-01 Merand Pharmaceuticals Inc Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
KR20230170690A (ko) 2021-03-26 2023-12-19 뉴미르나 테라퓨틱스 에이피에스 MicroRNA-134 억제제들
MX2023011101A (es) 2021-03-26 2024-01-10 Neumirna Therapeutics Aps Inhibidores de microrna-27b.
JP2024522272A (ja) 2021-06-04 2024-06-13 ニューミルナ セラピューティクス エーピーエス アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
AU2022329834A1 (en) 2021-08-17 2024-03-07 Korea Advanced Institute Of Science And Technology Antisense oligonucleotide targeting cav3.1 gene and uses thereof
EP4388096A1 (de) 2021-08-19 2024-06-26 Neumirna Therapeutics ApS Antisense oligonukleotide gegen adenosinkinase
EP4332239A1 (de) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
EP4450626A1 (de) 2023-04-21 2024-10-23 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Frnip2-inhibitoren zur behandlung von ataxie telangiectasia
WO2025015676A1 (zh) * 2023-07-21 2025-01-23 瑞孚医药科技（广州）有限公司 碳环核苷、寡核苷酸及其制备方法和医药用途
EP4512899A1 (de) 2023-08-23 2025-02-26 Lipigon Pharmaceuticals AB Angptl4-aso-zusammensetzungen zur behandlung von atherosklerose bei menschen
WO2026068729A1 (en) 2024-09-26 2026-04-02 Neumirna Therapeutics Aps Antimir-27b for treatment of parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE356824T1 (de) * 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
EP1334109B1 (de) * 2000-10-04 2006-05-10 Santaris Pharma A/S Verbesserte synthese von purin-blockierten nukleinsäure-analoga

Also Published As

Publication number Publication date
WO2003095467A1 (en) 2003-11-20
DE60315444D1 (en) 2007-09-20
EP1501848A1 (de) 2005-02-02
DE60315444T2 (de) 2008-04-30
CA2484526A1 (en) 2003-11-20
AU2003222743A1 (en) 2003-11-11
EP1501848B1 (de) 2007-08-08
CA2484526C (en) 2009-10-13
AU2003222743B2 (en) 2008-12-11
JP4476802B2 (ja) 2010-06-09
DK1501848T3 (da) 2007-10-22
ES2290448T3 (es) 2008-02-16
JP2005532319A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
DE60315444D1 (en) Synthese von locked nucleic acid-derivaten
UA95600C2 (en) Synthesis scheme for lacosamide
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
WO2009137455A3 (en) Cure accelerators for anaerobic curable compositions
MY150490A (en) Improved process for producing hydrocyanic acid
WO2005005389A3 (en) Malonamide derivatives
GEP20125512B (en) Process for synthesis of agomelatin
IL208290A0 (en) Process for the preparation of 10-deacetyl-bis-7, 10- trichloroacetylbaccatin iii
WO2009075890A8 (en) Method for synthesis of triazole compounds that modulate hsp90 activity
WO2008077600B1 (en) Compounds and methods for synthesis and purification of oligonucleotides
GB0520085D0 (en) Oligomerisation of olefinic compounds in the presence of an oligomerisation catalyst, and a catalyst activator including a halogenated -AR group
WO2009083532A3 (en) Novel method for the preparation of derivatives of dihydrotetraazapentacenes, products such as obtained, and uses thereof
TW200638930A (en) Acetylene derivatives
IL172015A0 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
Jafarpour et al. Catalytic activity of silica gel in the synthesis of sulfonamides under mild and solvent-free conditions
IL183805A0 (en) Process for preparing substituted thiophenesulfonyl isocyanates
Liu et al. N-methylimidazole as a promising catalyst for the aza-Michael addition reaction of N-heterocycles
US7723495B2 (en) Amidite for nucleic acid synthesis and nucleic acid synthesizing method
PL356929A1 (en) Process for the synthesis of a known tetrazol derivative
TW200716544A (en) Organic compounds
WO2007066158A3 (en) HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
DE602006005349D1 (de) Verfahren zur herstellung von hydrazon-derivaten
WO2007049295A3 (en) An improved one pot process for making key intermediate for gemcitabine hcl
WO2008015133A3 (en) Process for preparing amidrazones

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties